版本:
中国

BRIEF-Amarin says vascepa showed reductions in potentially atherogenic lipid parameters

June 12 Amarin Corporation Plc

* Amarin says vascepa showed reductions in potentially atherogenic lipid parameters in statin-treated women with type 2 diabetes and persistent high triglycerides

* Amarin Corp says vascepa significantly increased blood EPA levels

* Amarin Corp - efficacy and safety of vascepa 4 g/day in women were consistent with overall anchor study results

* Amarin Corp expects trial will run to completion and onset of target final primary cardiovascular event will likely be reached near end of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐